Orexo AB

383 articles about Orexo AB

• Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

  4/17/2024

  Orexo AB, announces that the United States Patent and Trademark Office has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.

• Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

  4/2/2024

  On March 13, 2024, Orexo AB, announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 .

• Correction: Notice of Annual General Meeting of Orexo

  3/22/2024

  The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.

• Notice of Annual General Meeting of Orexo - March 15, 2024

  3/15/2024

  The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.

• Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds

  3/13/2024

  Orexo AB, has successfully issued new senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years.

• Orexo and Sobi agree to advance feasibility study with AmorphOX

  2/12/2024

  Orexo AB, announces the company agreed with Swedish Orphan Biovitrum AB to advance the successful exploratory feasibility study initiated last year.

• Orexo Interim Report Q4 2023, incl. Full Year Report

  2/8/2024

  The MODIA® study didn't meet the ­primary end-points, but showed high rates of treatment ­response in both study arms, with no adverse events associated with the use of MODIA.

• Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

  2/6/2024

  Orexo AB, announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

• Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

  11/28/2023

  Orexo AB, announces the New Drug Application for OX124 has been accepted for review by the US Food and Drug Administration.

• Orexo Q3 2023 Interim Report

  11/2/2023

  The MODIA® study didn't meet the ­primary end-points, but showed high rates of treatment ­response in both study arms, with no adverse events associated with the use of MODIA.

• Orexo announces changes in the company´s Board of Directors - October 27, 2023

  10/27/2023

  Orexo AB, announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

• Report from Orexo´s extraordinary general meeting - October 26, 2023

  10/26/2023

  The extraordinary general meeting in Orexo AB on 26 October 2023 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members.

• Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids

  10/11/2023

  Orexo AB, reports top line results after having completed a study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder and reduction in use of illicit opioids.

• Notice of Extraordinary General Meeting in Orexo AB (publ)

  10/3/2023

  Orexo AB, Reg. No. 556500-0600, with its registered office in Uppsala, gives notice of the Extraordinary General Meeting to be held on 26 October 2023 at 15:00 CEST at Advokatfirman Vinge's premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden.

• Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023

  9/5/2023

  Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) , today announces the company will participate in Pareto Securities' 14th  Annual Healthcare Conference, that takes place on September 14 , at Hotel At Six, Brunkebergstorg 6, Stockholm, Sweden.

• Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

  8/29/2023

  Orexo AB, announces that the United States Patent and Trademark Office has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.

• Orexo Q2 2023 Interim Report

  7/18/2023

  EBITDA of SEK 5.6 m (-32.5), EBITDA excluding legal costs and costs for non-­repeating ­clinical trials, SEK 30.3 m (11.4)

• Orexo Interim Report Q1 2023

  4/27/2023

  Exploratory feasibility studies of amorphOX® initiated in collaboration with two international biopharmaceutical and vaccine companies.

• Report from Orexo AB's annual general meeting - April 18, 2023

  4/18/2023

  The annual general meeting in Orexo AB on 18 April 2023 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members.

• Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124

  4/3/2023

  Orexo AB, announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, is delayed to late 2024 from previously first half of 2024, if approved by the US Food and Drug Administration according to their ordinary timelines.